{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:12:18Z","timestamp":1790759538280,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The IL-17 pathway is an established driver of psoriasis pathogenesis. We examined the detailed molecular and cellular effects of blockade of IL-17 signaling in human psoriatic skin before and following treatment with brodalumab, a competitive inhibitor of the IL-17 Receptor A subunit. Thousands of aberrantly expressed genes in lesional skin normalized within 2 weeks following brodalumab treatment, with conversion of the lesional psoriasis transcriptome to resemble that seen in nonlesional skin. Keratinocyte-expressed genes appeared to normalize rapidly, whereas T cell\u2013specific normalization occurred over six weeks. The three IL-17 ligand genes that are upregulated in lesional skin, IL17A, IL17C, and IL17F, were all downregulated in a dose-dependent manner following brodalumab treatment. Cellular measures also showed a similar pattern with dramatic decreases in keratinocyte hyperplasia within one week, and decreases in infiltrating leukocytes occurred over a longer timescale. Individuals with the highest brodalumab exposure showed normalization of both IL-17\u2013responsive genes and the psoriasis transcriptome, whereas subjects with lower exposures showed transient or incomplete molecular responses. Clinical and molecular response appeared dependent on the extent of brodalumab exposure relative to the expression of IL-17 ligand genes, and reduction of IL-17 signaling into the nonlesional range was strongly correlated with normalization of the psoriasis transcriptome. These data indicate that blockade of IL-17 signaling in psoriatic skin leads to rapid transcriptomal changes initially in keratinocyte-expressed genes, followed by normalization in the leukocyte abnormalities, and demonstrates the essential role of the IL-17R on keratinocytes in driving disease pathogenesis.<\/jats:p>","DOI":"10.4049\/jimmunol.1301737","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T05:23:45Z","timestamp":1395293025000},"page":"3828-3836","source":"Crossref","is-referenced-by-count":143,"title":["Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti\u2013IL-17 Receptor Monoclonal Antibody"],"prefix":"10.1093","volume":"192","author":[{"given":"Chris B","family":"Russell","sequence":"first","affiliation":[{"name":"Amgen , Seattle, WA 98119"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Rand","sequence":"additional","affiliation":[{"name":"Amgen , Seattle, WA 98119"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Bigler","sequence":"additional","affiliation":[{"name":"Amgen , Seattle, WA 98119"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Kerkof","sequence":"additional","affiliation":[{"name":"Amgen , Seattle, WA 98119"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Timour","sequence":"additional","affiliation":[{"name":"Amgen , Seattle, WA 98119"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Bautista","sequence":"additional","affiliation":[{"name":"Amgen , Thousand Oaks, CA 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G","family":"Krueger","sequence":"additional","affiliation":[{"name":"Rockefeller University , New York, NY 10065"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Salinger","sequence":"additional","affiliation":[{"name":"Amgen , Seattle, WA 98119"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A","family":"Welcher","sequence":"additional","affiliation":[{"name":"Amgen , Thousand Oaks, CA 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Martin","sequence":"additional","affiliation":[{"name":"Amgen , Seattle, WA 98119"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,4,15]]},"reference":[{"key":"2025032404232445300_r1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clindermatol.2007.08.007","article-title":"Psoriasis: epidemiology","volume":"25","author":"Gudjonsson","year":"2007","journal-title":"Clin. Dermatol."},{"key":"2025032404232445300_r2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/1568010043343958","article-title":"Epidemiology of psoriasis","volume":"3","author":"Naldi","year":"2004","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"2025032404232445300_r3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"2025032404232445300_r4","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Sch\u00f6n","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2025032404232445300_r5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol."},{"key":"2025032404232445300_r6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"2025032404232445300_r7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.coi.2011.07.006","article-title":"Recent advances in the IL-17 cytokine family","volume":"23","author":"Gaffen","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"2025032404232445300_r8","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J. Immunol."},{"key":"2025032404232445300_r9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.2156","article-title":"IL-17C regulates the innate immune function of epithelial cells in an autocrine manner","volume":"12","author":"Ramirez-Carrozzi","year":"2011","journal-title":"Nat. Immunol."},{"key":"2025032404232445300_r10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025032404232445300_r11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","article-title":"Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis","volume":"122","author":"Capon","year":"2007","journal-title":"Hum. Genet."},{"key":"2025032404232445300_r12","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"2025032404232445300_r13","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti\u2011interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2025032404232445300_r14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti\u2011interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2025032404232445300_r15","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/jid.2012.163","article-title":"Anti\u2011IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial","volume":"132","author":"Papp","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"2025032404232445300_r16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025032404232445300_r17","first-page":"175","article-title":"Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies","volume":"1","author":"Endres","year":"2012","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"2025032404232445300_r18","doi-asserted-by":"crossref","first-page":"e52242","DOI":"10.1371\/journal.pone.0052242","article-title":"Cross-study homogeneity of psoriasis gene expression in skin across a large expression range","volume":"8","author":"Bigler","year":"2013","journal-title":"PLoS One"},{"key":"2025032404232445300_r19","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1073\/pnas.0409569102","article-title":"Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris","volume":"102","author":"Chamian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032404232445300_r20","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-98141-3","volume-title":"ggplot2: elegant graphics for data analysis.","author":"Wickham","year":"2009"},{"key":"2025032404232445300_r21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0074-7742(04)60002-X","article-title":"Experimental design and low-level analysis of microarray data","volume":"60","author":"Bolstad","year":"2004","journal-title":"Int. Rev. Neurobiol."},{"key":"2025032404232445300_r22","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"2025032404232445300_r23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"2025032404232445300_r24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"2025032404232445300_r25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"2025032404232445300_r26","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and T cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood"},{"key":"2025032404232445300_r27","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/hmg\/ddt034","article-title":"Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis","volume":"22","author":"Johnston","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"2025032404232445300_r28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"2025032404232445300_r29","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/jid.2011.458","article-title":"A single intradermal injection of IFN-\u03b3 induces an inflammatory state in both non-lesional psoriatic and healthy skin","volume":"132","author":"Johnson-Huang","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"2025032404232445300_r30","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar3781","article-title":"Functional role of IL-22 in psoriatic arthritis","volume":"14","author":"Mitra","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"2025032404232445300_r31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23\u2011induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"2025032404232445300_r32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/intimm\/dxr110","article-title":"IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1\u03b2 by keratinocytes via the ROS-NLRP3-caspase-1 pathway","volume":"24","author":"Cho","year":"2012","journal-title":"Int. Immunol."},{"key":"2025032404232445300_r33","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.4049\/jimmunol.0902464","article-title":"Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1\u03b1, and TNF-\u03b1 recapitulates some features of psoriasis","volume":"184","author":"Guilloteau","year":"2010","journal-title":"J. Immunol."},{"key":"2025032404232445300_r34","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J. Exp. Med."},{"key":"2025032404232445300_r35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"2025032404232445300_r36","doi-asserted-by":"crossref","first-page":"xiv","DOI":"10.1111\/j.0022-202X.2005.23923.x","article-title":"Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha","volume":"125","author":"Nestle","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"2025032404232445300_r37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch. Dermatol."},{"key":"2025032404232445300_r38","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br. J. Dermatol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/192\/8\/3828\/61758801\/1301737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/192\/8\/3828\/61758801\/1301737.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T08:16:24Z","timestamp":1742804184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/192\/8\/3828\/8001432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,4,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1301737","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,4]]},"published":{"date-parts":[[2014,4]]}}}